» Articles » PMID: 8529093

Regulation of Transcription Functions of the P53 Tumor Suppressor by the Mdm-2 Oncogene

Overview
Journal Mol Med
Publisher Biomed Central
Date 1995 Jan 1
PMID 8529093
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mdm-2, a zinc finger protein, negatively regulates the p53 tumor suppressor gene product by binding to it and preventing transcriptional activation (16).

Materials And Methods: Assays for p53 mediated transcription, repression and activation by mutant and wild-type p53 proteins were used to measure the ability of mdm-2 to block each activity.

Results: Mdm-2 was able to inhibit all three functions of the wild-type and mutant p53 activities; transcriptional activation by the wild-type protein, transcriptional activation by the mutant p53 protein, and repression by the wild-type protein.

Conclusions: The mdm protein binds to the amino terminal portion of the p53 protein and, in so doing, blocks the ability of p53 to interact with the transcriptional machinery of the cell (23). The mdm-2 protein binds to both leucine-tryptophan residues at amino acids 22 and 23, from the amino terminal end of the protein, and in so doing, prevents all p53 functions. The ability of a mutant p53 protein to transactivate a multidrug resistance-1 gene promoter is blocked by mdm-2 and the ability of the wild-type p53 protein to repress transcription of some genes is also blocked by the mdm-2 protein. Thus, all three functions of the p53 protein-transcriptional activation, repression and mutant protein activation-require the p53 amino terminal domain functions and are regulated by the mdm-2 protein in a cell. When mdm-2 is overproduced, resulting in a tumor or transformation of a cell, all of the p53 activities are inactivated.

Citing Articles

The Ubiquitination of Arrestin3 within the Nucleus Triggers the Nuclear Export of Mdm2, Which, in Turn, Mediates the Ubiquitination of GRK2 in the Cytosol.

Kundu D, Min X, Zhang X, Tian X, Wang S, Kim K Int J Mol Sci. 2024; 25(17).

PMID: 39273591 PMC: 11395016. DOI: 10.3390/ijms25179644.


A testis-specific lncRNA functions as a post-transcriptional regulator of MDM2 and stimulates apoptosis of testicular germ cell tumor cells.

Ito S, Ueno A, Ueda T, Ogura R, Sako S, Gabata Y Cell Death Discov. 2024; 10(1):348.

PMID: 39097584 PMC: 11297958. DOI: 10.1038/s41420-024-02119-8.


Phospholipase A and acyltransferase 4/retinoic acid receptor responder 3 at the intersection of tumor suppression and pathogen restriction.

Zhao J, Yuan X, Luo R, Wang L, Gu W, Yamane D Front Immunol. 2023; 14:1107239.

PMID: 37063830 PMC: 10102619. DOI: 10.3389/fimmu.2023.1107239.


p53 Isoforms as Cancer Biomarkers and Therapeutic Targets.

Zhao L, Sanyal S Cancers (Basel). 2022; 14(13).

PMID: 35804915 PMC: 9264937. DOI: 10.3390/cancers14133145.


Advances in the Structural and Physiological Functions of SHARPIN.

Yu B, Wang F, Wang Y Front Immunol. 2022; 13:858505.

PMID: 35547743 PMC: 9084887. DOI: 10.3389/fimmu.2022.858505.


References
1.
Kuerbitz S, Plunkett B, Walsh W, Kastan M . Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992; 89(16):7491-5. PMC: 49736. DOI: 10.1073/pnas.89.16.7491. View

2.
Lin J, Chen J, Elenbaas B, Levine A . Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 1994; 8(10):1235-46. DOI: 10.1101/gad.8.10.1235. View

3.
Seto E, Usheva A, Zambetti G, Momand J, Horikoshi N, Weinmann R . Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A. 1992; 89(24):12028-32. PMC: 50691. DOI: 10.1073/pnas.89.24.12028. View

4.
Finlay C . The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol. 1993; 13(1):301-6. PMC: 358909. DOI: 10.1128/mcb.13.1.301-306.1993. View

5.
Oliner J, Pietenpol J, Thiagalingam S, Gyuris J, Kinzler K, Vogelstein B . Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993; 362(6423):857-60. DOI: 10.1038/362857a0. View